Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.

British journal of cancer - 12 Jul 2016

Lo Michelle Chin I, Paterson Anna, Maraka Jane, Clark Richard, Goodwill Joseph, Nobes Jenny, Garioch Jennifer, Moncrieff Marc, Rytina Ed, Igali Laszlo

Abstract excerpt

BACKGROUND: Determining the BRAF mutation status of patients with advanced metastatic melanoma is essential in order to assess patients' eligibility for targeted BRAF inhibitor therapy. The aim of this study was to validate the utility of immunohistochemistry (IHC) to rapidly obtain the BRAF status in the UK cancer centre setting. METHODS: All samples sent for molecular testing for detection of the BRAF mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Feasibility Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Melanoma

Share to Mutation

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins B-raf

Share to United Kingdom

Source

Open in PubMed Open full text

Identifiers

PMID: 27336602
DOI: 10.1038/bjc.2016.106
PMCID: PMC4947692

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.PMID 27336602Read ↗

Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma.Semantic proximity Read ↗

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.Semantic proximity Read ↗

BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.Semantic proximity Read ↗

Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.Semantic proximity Read ↗

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.Semantic proximity Read ↗

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.Semantic proximity Read ↗

BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.Semantic proximity Read ↗

[Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].Semantic proximity Read ↗

BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases.Semantic proximity Read ↗

Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.Semantic proximity Read ↗

Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.Semantic proximity Read ↗

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.